5 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 4 Phase 2, 4 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 4 | Active not recruiting 1, Completed 1, Recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow Medicure: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Continuation Study With Oral MC-1 for Treatment of Patients With PNPO-Deficiency Pyridoxal 5'-Phosphate - Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | Phase 3 | Recruiting | Medicure | 10 | 2025-07-15 | 2026-11-10 |
| Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency Pyridoxal Phosphate - Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency | Phase 3 | Active not recruiting | Medicure | 15 | 2024-02-16 | 2026-11-19 |
| Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function Tirofiban - Renal Insufficiency | Phase 1 | Completed | Medicure | 25 | 2013-01-01 | 2014-03-27 |
| Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention Short Tirofiban, Eptifibatide, Long Tirofiban - Myocardial Infarction, Acute Coronary Syndromes | Phase 2 | Completed | Medicure | 535 | 2012-04-01 | 2021-05-13 |
| Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia Pyridoxal 5'-Phosphate, Placebo - Tardive Dyskinesia | Phase 2 | Terminated | Medicure | 53 | 2009-05-01 | 2019-02-15 |
| A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG (MC-1) Pyridoxal 5'-phosphate - Coronary Artery Bypass Graft Surgery, Myocardial Ischemia | Phase 3 | Completed | Medicure | 3000 | 2006-11-01 | 2007-11-16 |
| MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics) pyridoxal-5'-phosphate with and without ACE inhibitor - Diabetes Mellitus Type 2, Hypertension | Phase 2 | Completed | Medicure | 160 | 2004-08-01 | 2006-10-31 |
| MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery) (MC-1) Pyridoxal-5'-phosphate - Coronary Artery Bypass Graft Surgery, Myocardial Ischemia | Phase 2 | Completed | Medicure | 900 | 2004-04-01 | 2006-10-31 |
| Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention Tirofiban (Aggrastat), Placebo - Myocardial Infarction, Acute Coronary Syndromes | Phase 3 | Withdrawn | Medicure | 2018-03-13 |
Acute Coronary Syndrome (2) · Angina, Unstable (2) · Ischemia (2) · Myocardial Infarction (2) · Myocardial Ischemia (2) · Neurologic Manifestations (2) · Reperfusion Injury (2) · Diabetes Mellitus, Type 2 (1) · Hypertension (1) · Metabolic Syndrome (1) · Renal Insufficiency (1) · Schizophrenia (1) · Tardive Dyskinesia (1)
Pyridoxal Phosphate (6) · Tirofiban (3) · Angiotensin-Converting Enzyme Inhibitors (1) · Eptifibatide (1)
United States (6) · Canada (4) · Australia (2) · India (1) · Poland (1)
Steven V Manoukian, MD (2) · Gary J. Remington, MD, PhD (1) · Jean-Claude Tardif, MD, FRCPC, FACC (1) · John Hill, MD (1) · Michel Carrier, MD (1) · Robert A Harrington, MD (1) · Yves Lacourciere, MD, FRCP (1)